Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 65 Solid TresibaⓇ performance strengthens basal insulin market share in Japan Japanese basal value market shares LevemirⓇ glargine U100 biosimilar glargine U100 - Novo Nordisk Japanese total insulin value market shares Eli Lilly - Sanofi glargine U300 NN Total Basal 80% TresibaⓇ NPH 70% 60% 50% 40% 30% 20% 10% 0% Aug 2015 Source: IQVIA monthly MAT Aug, 2018 value figures changing diabetes 60% 52% 44% 40% 17% -15% 20% 14% 6% 2% 0% Aug 2018 Aug 2015 Source: IQVIA monthly MAT Aug, 2018 value figures 60% 22% 18% Aug 2018 novo nordisk

View entire presentation